Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

v3.3.1.900
Commitments and Contingencies (Details Textual)
 1 Months Ended 12 Months Ended
Feb. 27, 2014
USD ($)
Aug. 28, 2012
USD ($)
patients
Jul. 24, 2012
USD ($)
Jun. 15, 2012
USD ($)
Dec. 31, 2007
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Dec. 31, 2012
USD ($)
Sep. 30, 2014
USD ($)
Commitments and Contingencies (Textual)                    
Research recorded fees           $ 13,311,739 $ 12,267,313 $ 3,109,331    
Security deposit             34,733      
Letter of credit             34,733      
Manufacturing Agreement [Member]                    
Commitments and Contingencies (Textual)                    
Project estimated cost for clinical trials of drug Ac-225-HuM195 $ 5,000,000         1,500,000        
Non - refundable institutional fee $ 600,000                  
Total project estimated to cost           100,000 700,000      
Research and development costs           4,200,000 3,600,000      
Einstein [Member]                    
Commitments and Contingencies (Textual)                    
Total project estimated to cost                   $ 200,000
Research and development costs           100,000 100,000      
AbbVie Biotherapeutics Corp [Member] | Product Development and Patent License Agreement [Member]                    
Commitments and Contingencies (Textual)                    
License fee payment           3,000,000        
Milestones payments           $ 7,750,000        
Description of royalty payment           Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.        
Royalty of net sales percentage           12.00%        
First commercial sale period           12 years 6 months        
AbbVie Biotherapeutics Corp [Member] | After First Net Sales [Member]                    
Commitments and Contingencies (Textual)                    
Milestones payments           $ 1,500,000        
AbbVie Biotherapeutics Corp [Member] | Phase I Clinical Trial of a licensed product [Member]                    
Commitments and Contingencies (Textual)                    
Milestones payments     $ 750,000     750,000        
Abbott Biotherapeutics Corp [Member] | After First Net Sales [Member] | Product Development and Patent License Agreement [Member]                    
Commitments and Contingencies (Textual)                    
Net sales in milestones payment           10,000,000        
Oak Ridge National Laboratory [Member]                    
Commitments and Contingencies (Textual)                    
Research and development costs           $ 800,000 600,000 300,000    
Aptiv Solutions [Member]                    
Commitments and Contingencies (Textual)                    
Down payment of project estimated cost percentage           12.50%        
Down payment for project         $ 200,000 $ 1,900,000     $ 200,000  
Total project estimated to cost           2,700,000        
Research and development costs           $ 400,000 400,000 300,000    
Fred Hutchinson Cancer Research Center [Member] | license and sponsored research agreement [Member]                    
Commitments and Contingencies (Textual)                    
Milestones payments       $ 1,000,000            
Description of royalty payment           Royalty payments of 2% of net sales will be due to FHCRC.        
Royalty of net sales percentage       2.00%            
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )       $ 200,000            
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )       300,000            
Research recorded fees           $ 300,000 200,000 $ 100,000    
Fred Hutchinson Cancer Research Center [Member] | Maximum [Member] | license and sponsored research agreement [Member]                    
Commitments and Contingencies (Textual)                    
Clinical trial cost for approval of food and drug administration       23,500,000            
Fred Hutchinson Cancer Research Center [Member] | Minimum [Member] | license and sponsored research agreement [Member]                    
Commitments and Contingencies (Textual)                    
Clinical trial cost for approval of food and drug administration       $ 13,200,000            
University of Texas M.D. Anderson Cancer Center [Member] | Clinical Trial Agreement [Member]                    
Commitments and Contingencies (Textual)                    
Number of Patients | patients   24                
Amount paid to each patient after Completing clinical trial   $ 500,000                
Start-up fee for clinical trial   $ 33,946                
Start-up due cost paid date   Dec. 31, 2015                
Non - refundable institutional fee   $ 14,500                
Research recorded fees           $ 100,000 $ 0